A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3011 ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS
The purpose of this research study is to test the safety of different doses of the BA3011 alone and in combination with nivolumab and to find out what effects, good and/or bad effects in individuals with locally advanced or metastatic solid tumor.
Advanced solid tumor that have failed available standard of care therapy
1. Individuals 12 years or older
2. Locally advanced or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply
12 - 100
Healthy Volunteers Needed
Duration of Participation
The study is planned to last for about 2 years. You will receive the study drug alone in combination with Nivolumab for as long as you and the investigator feel that you are tolerating the study drug and the investigator feels it is in your best interest to continue receiving study drug; you follow directions of the investigator; or if you are able to become pregnant, you do not become pregnant. After you finish treatment, you will have safety follow-up visits to see how you are feeling 3 months from your last dose of study drug. Thereafter, your investigator will continue to watch you for side effects and follow your condition every 3 months by telephone.
Knight Clinical Trials Information Line